- Strategic acquisitions of i.Bioceuticals in the US and
Biopress in France: - Strengthening the Group's solutions
for its many markets - Expansion of the offer in the
nutraceutical and agri-food markets - Securing a local
supply of plant-based raw materials
- 2023 Q1 revenue of €14.5 million, up 5.1%
Regulatory News:
Groupe Berkem (Paris:ALKEM), a leading player in bio-based
chemistry (ISIN code: FR00140069V2 - Ticker: ALKEM), announces
its revenue for the first quarter of 2023 and provides an update on
its recent activity.
Olivier FAHY, Chairman and CEO of Groupe Berkem
said: "In 2023, Groupe Berkem will continue to implement the
strategic plan announced at the time of its initial public
offering. The recent acquisitions of i.Bioceuticals and Biopress
have consolidated our growth model by ensuring, for the former, a
presence in the strategic nutraceutical market while strengthening
the Group's internationalisation and, for the latter, a local
supply of vegetable oils, essential raw materials for our numerous
activities aimed at industrialists. With a solid financial
structure and new assets to strengthen our position as a major
player in plant-based chemistry in France and internationally, we
reaffirm our financial objectives for 2024."
2023 Q1 revenue
Groupe Berkem will now present the allocation of its revenue
between its four business areas: Construction & Materials,
Hygiene & Protection, Health, Beauty & Nutrition and
Industry.
As of March 31, 2023, Groupe Berkem's revenue for the first
three months of 2023 reached €14.5m, compared to €13.8m in the
first quarter of 2022, corresponding to an increase of 5.1%:
in € thousands
T1 2023
T1 2022
Change
Construction & Materials
6,401
6,270
+2.1%
Hygiene & Protection
3,532
2,985
+18.3%
Health, Beauty & Nutrition
4,515
4,470
+1.0%
Industry
10
47
-78.2%
Other
43
31
+41.4%
TOTAL
14 500
13 802
+5.1%
The Construction & Materials division posted revenue
of €6.4m in Q1 2023, up 2.1% since 2022. The Hygiene &
Protection division, for its part, has increased by
+18.3% since 2022, to post revenue of €3.5m in Q1 2023. The sales
of i.Bioceuticals, acquired from INC, have been fully accounted for
since February 15, 2023, bringing the Health, Beauty &
Nutrition division's revenue to €4.5m in Q1 2023, +1%. Finally,
the Industry division had revenue of €0.01m in Q1 2023 and
corresponds to sales of resins for applications excluding the
Construction & Materials segment.
2023 Q1 AND POST-CLOSING
HIGHLIGHTS
External growth operations
Groupe Berkem announced in February 2023 the completion of
the acquisition of i.Bioceuticals, Inc. from the Dutch INC
(International Nutrition Company), the leading exclusive North
American distributor of nutritional ingredients. The acquisition of
this subsidiary allows the Group to distribute directly in North
America its complete range of antioxidant active ingredients and
thus broaden its offer by addressing the Nutraceutical business
segment.
Also, in early April 2023, the Group announced the strategic
acquisition of Biopress, a French producer of 100% vegetable
oils and proteins. With this operation, the Group now benefits from
a local supply of technical vegetable oils, consolidates its offer
for the "Health, Beauty & Nutrition" business line and secures
new commercial opportunities in the food market.
Activity
In March 2023, Groupe Berkem launched its new range of 100%
natural floral waters with 97.5% organic content, H2OLIXIR,
intended for the Health and Beauty industries.
At the beginning of April, the Group launched the marketing
of Termifuge K, a preventive, ready-to-use anti-termite and
waterproofing solution for the construction industry. This
over-activated solution reduces the content of conventional
biocides by 50% thanks to the integration of a plant-based
over-activator and the virtues of a plant-based insecticide,
formulated by the Berkem Group.
International and Regulatory
In March 2023, the Group announced the extension of its
distribution agreement with Unipex, already a distributor of
the Group's plant extracts for France, to the Benelux and
French-speaking Switzerland for all its ingredients for the
cosmetics and personal care markets.
In April 2023, Groupe Berkem continued to strengthen its
international expansion strategy by signing a partnership with
Kreglinger for the distribution of its cosmetic ingredients
in the UK.
CONFIRMATION OF FINANCIAL TARGETS FOR
2024
The Group confirms its ambition to achieve a revenue of at least
€85 million by 2024 following the external growth operations
carried out. By the same date, the Group's objective is to achieve
an EBITDA margin of around 25%.
2022 annual results and availability of
the 2022 annual financial report
Groupe Berkem has decided to present its 2022 financial
statements under IFRS. Given the adjustments that this conversion
requires, the 2022 annual results, as well as the 2022 financial
report, will now be published on May 16, 2023, after market
closing.
ABOUT THE BERKEM GROUP
Founded in 1993 by Olivier Fahy, Chairman and Chief Executive
Officer, Groupe Berkem is a leading force in the bio-based
chemicals market. Its mission is to advance the environmental
transition of companies producing the chemicals used in everyday
life (Construction & Materials, Health, Beauty & Nutrition,
Hygiene & Protection, and Industry). By harnessing its
expertise in both plant extraction and innovative formulations,
Groupe Berkem has developed bio-based boosters—unique high-quality
bio-based solutions augmenting the performance of synthetic
molecules. Groupe Berkem achieved revenue of €51.8 million in 2022.
The Group has almost 200 employees working at its head office
(Blanquefort, Gironde) and 3 production facilities in Gardonne
(Dordogne), La Teste-de-Buch (Gironde), and Chartres
(Eure-et-Loir).
Groupe Berkem has been listed on Euronext Growth Paris since
December 2021 (ISIN code: FR00140069V2 - ALKEM).
www.groupeberkem.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230427005749/en/
Groupe Berkem Olivier Fahy,
Chairman and CEO Anthony Labrugnas, Chief Financial Officer Phone:
+33 (0)5 64 31 06 60 investisseurs@berkem.com
NewCap Investor Relations
Mathilde Bohin / Nicolas Fossiez Phone: +33 (0)1 44 71 94 94
berkem@newcap.eu
NewCap Media Relations
Nicolas Merigeau / Antoine Pacquier Phone: +33 (0)1 44 71 94 94
berkem@newcap.eu
Grafico Azioni Groupe Berkem (EU:ALKEM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Groupe Berkem (EU:ALKEM)
Storico
Da Mag 2023 a Mag 2024
